Finally, given the diversity of AATD variants that exists and the unlikelihood that clinical evidence for AAT therapy efficacy for each variant will become available, we underline the importance of correct molecular diagnosis of AATD to provide the basis for the best management and treatment options in view of precise medicine. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.